Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dovitinib vs Sorafenib in metastatic renal cell carcinoma
NCT01223027Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2011
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 27
01
Overview
A Phase 3 trial of dovitinib in metastatic renal cell carcinoma (mRCC), sponsored by Novartis. Started Mar 2011; status: completed.
02
Drugs
dovitinib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT01223027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01223027.